ArticleJournal of dental sciences2023
Significantly higher serum levels and positive rates of tumor biomarkers in patients with oral lichen planus.
Article in Journal of dental sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Oral lichen planus (OLP) is generally considered as an oral potentially malignant disorder (OPMD). Previous studies have shown significantly higher serum carcinoembryonic antigen (CEA), squamous cell carcinoma-antigen (SCC-Ag), and ferritin levels in patients with OPMDs such as oral submucous fibrosis, oral leukoplakia, oral erythroleukoplakia, or oral verrucous hyperplasia. This study aimed to evaluate whether there were significantly higher serum levels and positive rates of CEA, SCC-Ag, and ferritin in OLP patients than in healthy control subjects. Materials and methods: The serum CEA, SCC-Ag, and ferritin levels in 106 OLP patients and 187 healthy control subjects were measured and compared. Patients with serum CEA level ≥3 ng/mL, SCC-Ag level ≥2 ng/mL, and ferritin level ≥250 ng/mL were scored as serum positive for CEA, SCC-Ag, and ferritin, respectively. Results: This study found significantly higher mean serum CEA and ferritin levels in 106 OLP patients than in 187 healthy control subjects. Moreover, 106 OLP patients had significantly higher serum positive rates of CEA (12.3%) and ferritin (33.0%) than 187 healthy control subjects. Although the mean serum SCC-Ag level was higher in 106 OLP patients than in 187 healthy control subjects, the difference was not statistically significant. Of the 106 OLP patients, 39 (36.8%), 5 (4.7%), and 0 (0.0%) had serum positivities of one, two, or three tumor biomarkers including CEA, SCC-Ag, and ferritin, respectively. Conclusion: Our findings indicate significantly higher serum levels and positive rates of CEA and ferritin in OLP patients than in healthy control subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.